Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Triple Negative Breast Cancer Day is only global event dedicated to triple negative breast cancer.
A look at the symptoms, treatments, risk factors, prognosis and research on breast cancer metastasis to the brain.
A novel clinical trial based on research from Cleveland Clinic’s Lerner Research Institute targets triple-negative breast cancer.
An estrogen receptor known as ERα plays a critical role in more than 70% of breast cancers.
The Food and Drug Administration recently approved the checkpoint inhibitor Keytruda (pembrolizumab).
An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.
Overall survival increased by 30% among women with aggressive breast cancer who began statin use post-diagnosis.
This is the first immunotherapy approved for previously untreated triple-negative breast cancer that is likely to relapse.
PARP inhibitor reduces the risk of disease recurrence in BRCA-positive people with high-risk early breast cancer.
The antibody-drug conjugate is the second drug approved for metastatic breast cancer in the course of a week.
Study offers assurance that the benefits of the combination can be achieved without diminishing patients’ quality of life.
First-line treatment with immunotherapy and a chemotherapy regimen extended progression-free survival by 35%.
Savage X Fenty, the pop superstar’s brand, is known for its dedication to inclusive representation in popular culture.
Adding Tecentriq to a three-drug chemotherapy regimen increases odds of remission of early-stage triple-negative breast cancer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.